Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation - Wikidata - awgldk - TriplyDB

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

http://www.wikidata.org/entity/Q24681317

about

Carvedilol in hypertension treatment Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol.The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis.Nebivolol (bystolic), a novel Beta blocker for hypertension Beta-blockers in the treatment of hypertension: are there clinically relevant differences?Diagnosis and Management of Systemic Sclerosis: A Practical Approach.Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.Advancements in pharmacotherapy for angina.Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction New Insights into Dialysis Vascular Access: Impact of Preexisting Arterial and Venous Pathology on AVF and AVG Outcomes.Neither K+ channels nor PI3K/Akt mediates the vasodilative effect of nebivolol on different types of rat arteries.Vasodilator β-blockers: a different class of antihypertensive agents?Does nebivolol prevent contrast-induced nephropathy in humans?The effect of nebivolol on internal mammary artery blood flow during coronary artery bypass graft surgery.

P2860

Q24642654-9529F2BD-EE6D-440C-A072-2B46085762A8 Q33902610-183E64B4-0268-4C81-8691-9B3214EDDB10 Q35623864-C3D049C3-D994-4180-9034-27E635CA9C76 Q36576745-96888897-71B4-476D-B7E5-ACCB2EA24EE0 Q37229207-751F9D23-4F79-41F8-B207-727D266C769B Q37505881-E4808A9E-7FEF-4E55-B727-E5188CC06567 Q38667111-6DB3BD62-D6BA-4685-A38A-88ACB66F1529 Q38913816-2227A47E-337A-493D-AFB4-F6603E9AA1FF Q39157832-18F3BD94-4B9A-436E-BAF1-604471F8028E Q39164200-E2919A94-4B59-4D84-B90A-E505AB3BEF8A Q40761254-5B757A58-27B8-4590-AF20-E688730996C1 Q42054472-9AAF6E3A-281C-46BA-9A35-D012170E802D Q43244752-F2CD6513-E7C6-45EB-87F8-C9714EF90291 Q48670874-CA0ED40C-9FBF-4B8F-9234-CF8D1B4A4AD5 Q51441863-CFEA51D0-06E3-4781-8B54-F0FA03D8CA51 Q53721454-1C41F5BB-729B-4C8E-BDAD-A9553763A51E

P2860

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

http://www.wikidata.org/entity/Q24681317

description

2006 nî lūn-bûn

@nan

2006 թուականին հրատարակուած գիտական յօդուած

@hyw

2006 թվականին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@ast

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@en

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@nl

type

label

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@ast

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@en

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@nl

prefLabel

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@ast

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@en

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@nl

P1433

Q24681317-64112EE5-BD17-4FFC-8F8A-6523CC7F9EBB

P1476

Q24681317-D132F510-110A-4893-93AA-BC332F036FB9

P2093

Q24681317-FC34DDFD-44CD-42F6-AA9F-9B7E6F9C6FF5

P2860

Q24681317-0AA59F05-D06F-46B3-A9A3-A62E08BE1DCA

Q24681317-0E741FD1-DC6F-4227-BA1A-22165A3FD097

Q24681317-18D89C34-5F87-4448-8376-EFB4CEB646DA

Q24681317-1DD42CC0-9041-456C-A85B-B4FBB3D90B98

Q24681317-31CD083B-B82E-4186-A1B8-2B2979315571

Q24681317-333CAE1D-D700-48A5-B635-6DDBA1A338EE

Q24681317-413708C1-4EED-402C-AE32-E8B50CAFD2BA

Q24681317-4A35DBBD-3CB2-42B9-9BDD-A3DAFEE50781

Q24681317-4ACC207E-8002-4E16-A2B5-0F3DEC621C93

Q24681317-4CE22B0E-DD46-4949-BC19-1E03AD9ED2E5

P304

Q24681317-DB1BE6F3-9F7C-471F-A852-B24CAE26EDAE

P31

Q24681317-8BA82895-A4D5-4231-A04E-8C700691239B

Q24681317-F422861F-E458-4BE4-A62F-4E7950B2B9C9

P356

Q24681317-D3EBBD0F-4762-4F3C-8DE8-BBFB46D5EFEC

P407

Q24681317-82C90149-7F6D-4DE1-981D-57DED3413E08

P433

Q24681317-92260B68-4F18-42D7-9BB9-70522DC1269B

P478

Q24681317-165E18ED-DF33-4C52-951E-89A872B93B9E

P577

Q24681317-11179232-41D7-4CAF-ADE5-882A363469B8

P5875

Q24681317-68920EBD-9EE2-4CE0-B4BD-5DA126E39972

P698

Q24681317-2676AB9F-9035-4ADC-817A-FBFC16F3767A

P921

Q24681317-1C7F756A-0B70-44E4-BC31-5FE30C7B4FF0

Q24681317-4573812B-3B20-4959-AF8E-A74E093884AB

Q24681317-6A0E5C73-C302-4171-B8CB-C17400613793

Q24681317-C9E35920-B5C1-4CB5-B598-A6BBEC141057

Q24681317-F73E0174-4BE1-4994-9BAC-39B1F5BA5824

P932

Q24681317-F672F3D0-271A-49CF-B4E7-032316EB0D6C

P356

VHRM.2006.2.3.303

P1433

Vascular Health and Risk Management

P1476

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation

@en

P2093

Robert Weiss

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

The role of the new beta-blockers in treating cardiovascular disease

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress.

Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994.

Nebivolol in the management of essential hypertension: a review.

Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.

Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients.

PM frequencies of major CYPs in Asians and Caucasians.

P304

303-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/VHRM.2006.2.3.303

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6480828

http://www.w3.org/2001/XMLSchema#string

P698

17326335

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

mechanism of action

P932

1993984

http://www.w3.org/2001/XMLSchema#string